Effect of exercise combined with glucagon‐like peptide‐1 receptor agonist treatment on cardiac function: Arandomized double‐blind placebo‐controlled clinical trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In patients with type 2 diabetes, both supervised exercise and treatment with the glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist ( GLP‐1RA ) liraglutide may improve cardiac function. We evaluated cardiac function before and after 16 weeks of treatment with the GLP‐1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin. Early diastolic myocardial tissue velocity was improved by exercise in the placebo group (mean ± standard deviation [s.d.] −7.1 ± 1.6 to −7.7 ± 1.8 cm/s, P = .01), but not in the liraglutide group (−7.1 ± 1.4 to −7.0 ± 1.4 cm/s, P = .60; between groups, P = .02). Similarly, the mean ± s.d. ratio of early and atrial mitral annular tissue velocities improved in the placebo group (1.0 ± 0.4 to 1.2 ± 0.4, P = .003), but not in the liraglutide group (1.0 ± 0.3 to 1.0 ± 0.3, P = .87; between groups, P = .03). We found no significant differences in heart rate, left ventricular ( LV ) structure or function within or between the groups. In conclusion, the addition of liraglutide to exercise in sedentary patients with dysregulated type 2 diabetes may blunt the suggested beneficial effect of exercise on LV diastolic function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
From, A. M., Scott, C. G., & Chen, H. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.003 · Cited by 469
Improved diastolic function in type 2 diabetes after a six month liraglutide treatment
Saponaro, F., Sonaglioni, A., Rossi, A., Montefusco, L., Lombardo, M., Adda, G., & Arosio, M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.046 · Cited by 41
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“However, the weight-lowering effects of GLP-1 RAs can probably be modulated by lifestyle measures aiming at reduced calorie intake [90], although a systematic examination of the combined efficacy of initiating treatment with GLP-1 RAs and patient education aiming at optimizing the weight-reducing effects of GLP-1 RAs…”
BackgroundBizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0857-6 · Cited by 137
Newman, A. A., Grimm, N. C., Wilburn, J. R., Schoenberg, H. M., Trikha, S. R. J., Luckasen, G. J., Biela, L. M., Melby, C. L., & Bell, C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01741 · Cited by 50
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
Metadata
- Authors
- Jørgensen, P. G., Jensen, M. T., Mensberg, P., Storgaard, H., Nyby, S., Jensen, J. S., Knop, F. K., & Vilsbøll, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-20
- Volume
- 19
- Issue
- 7
- Pages
- 1040-1044
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2586303576
- Cited by
- 36
- References
- 4
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.